EyePoint Pharmaceuticals has announced positive interim masked safety data for its investigational EYP-1901 for treatment of moderate to severe nonproliferative diabetic retinopathy and wet age-related macular degeneration.
According to a company press release, EYP-1901 combines EyePoint’s proprietary sustained delivery technology and vorolanib, a tyrosine kinase inhibitor. The investigational product is currently being evaluated as a 9-month treatment for nonproliferative diabetic retinopathy (NPDR) in the phase 2 PAVIO trial and as a 6-month treatment for wet AMD in the phase 2 DAVIO 2